Clinical Trial Evaluating NuShield® Plus Standard of Care (SOC) Versus Standard of Care (SOC) Alone in the Management of Non-Healing Venous Leg Ulcers (VLUs)
← catalyst calendarNCT07510412 · readout ≤ 984 d
Sponsored by Organogenesis (industry) · ORGO — their whole pipeline →. With Professional Education and Research Institute.
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
200estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-18 | estimated | When the study began enrolling |
| Primary completion | Apr 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Venous Leg Ulcers
Intervention
- Other: NuShield®
Primary outcome
what the primary-completion date above is the date OFThe proportion of subjects that obtain complete closure
measured 16 weeks
Permalink · ORGO's whole pipeline · Catalyst calendar · Every registered study · What changed